Anti-CEA Antibodies
AssigneeRoche Glycart AG
InventorsThomas U. Hofer, Ralf Hosse, Ekkehard Moessner, Pablo Umana
Life of this patent
Estimating the term…
Abstract
The present invention provides antigen binding molecules (ABMs) which bind membrane-bound CEA, including ABMs with improved therapeutic properties, and methods of using the same.
Claims24
An isolated antibody which binds membrane-bound CEA, wherein the antibody comprises a heavy chain variable region comprising:
- a heavy chain CDR1 selected from the group consisting of SEQ ID NO:
- 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:
- 10, and SEQ ID NO:12,
- a heavy chain CDR2 selected from the group consisting of SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:
- 17, SEQ ID NO:
- 18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, and SEQ ID NO:24,
- a heavy chain CDR3 selected from the group consisting of SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219 SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, and SEQ ID NO:224, and
- a light chain CDR1 selected from the group consisting of SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, and SEQ ID NO:45, and
- a light chain CDR2 selected from the group consisting of SEQ ID NO:46, and SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, and SEQ ID NO:55, and
- a light chain CDR3 of SEQ ID NO:56.
An isolated antibody which binds membrane-bound CEA, wherein the antibody comprises a heavy chain variable region comprising an amino acid sequence that is at least 95% identical to a sequence selected from the group consisting of SEQ ID NO:
- 233, SEQ ID NO:
- 234, SEQ ID NO:
- 235, SEQ ID NO:
- 239, SEQ ID NO:
- 241, SEQ ID NO:
- 242, SEQ ID NO:
- 243, and SEQ ID NO:
- 247 and a light chain variable region comprising an amino acid sequence that is at least 95% identical to the sequence of SEQ ID NO:
- 209, and wherein the antibody has at least about 2-fold increase in stability as compared to PR1A3 or a humanized version of PR1A3.
An isolated antibody which binds membrane-bound CEA, wherein the antibody comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
- 233, SEQ ID NO:
- 234, SEQ ID NO:
- 235, SEQ ID NO:
- 239, SEQ ID NO:
- 241, SEQ ID NO:
- 242, SEQ ID NO:
- 243, and SEQ ID NO:
- 247 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
- 209.
The method of claim 24, wherein the antibody is administered in combination with chemotherapy or radiation therapy.
Dependencies are inferred from the claim text.